Characterization of <i>Pseudomonas aeruginosa</i> resistance to ceftolozane-tazobactam due to <i>ampC</i> and/or <i>ampD</i> mutations observed during treatment using semi-mechanistic PKPD modeling
Luc Deroche(Inserm), Julien M. Buyck(Inserm), Olivier Barraud(Inserm), Vincent Aranzana‐Climent(Inserm), Nicolas Grégoire(Inserm), Laure Prouvensier(Inserm), Sandrine Marchand(Inserm), Albane Rozenholc(Inserm), Léa Darnaud(Inserm), Marie-Cécile Ploy(Université de Limoges), Bruno François(Inserm), William Couet(Inserm)
Cited by 6
Related Papers
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
The SOFA score—development, utility and challenges of accurate assessment in clinical trials
|Critical Care|2019|976
Hydrocortisone plus Fludrocortisone for Adults with Septic Shock
|New England Journal of Medicine|2018|894
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
|New England Journal of Medicine|2005|890